8
8
6
6
1
1
4
4
16
16
20
20
10
10
15
15
20
20
23
23
2019
2010
Company (128)Hospital (2)University (2)
1 - 10 of 128
Sort by
SEC Filing
Accession Number0001567619-19-013151Form TypeDAcceptance Date2019-06-10
Sold $3,002,356 of $13,879,793 of Equity
Patent
Publication NumberAU 2017367730 A1StatusPatent ApplicationAvailabilityUnknownFiling Date2017-12-01Publication Date2019-06-06
This present disclosure relates to methods and compositions comprising biologically active nanoparticle formulations of MYC protein. Provided are methods of making the nanoparticle formulations and methods of using the nanoparticle formulations for treatment.
Patent
Publication NumberEP 3490584 A1StatusPatent ApplicationAvailabilityUnknownFiling Date2017-08-03Publication Date2019-06-05
Clinical Trial
Clinical Trial IDNCT02860559Start Date2019-09-01Completion Date2023-03-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second g…
Clinical Trial
Clinical Trial IDNCT03385486Start Date2019-06-01Completion Date2022-04-01PhasePhase 1Study TypeInterventionalStatusRecruiting
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
Patent
Publication NumberIL 265409 D0StatusPatent ApplicationAvailabilityUnknownFiling Date2019-03-17Publication Date2019-05-30
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
Patent
Publication NumberIL 264977 D0StatusPatent ApplicationAvailabilityUnknownFiling Date2019-02-21Publication Date2019-05-30
Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
Patent
Publication NumberUS 20190142870StatusPatent ApplicationAvailabilityUnknownFiling Date2019-01-29Publication Date2019-05-16
The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC)…
Patent
Publication NumberEP 2970898 B1StatusIssued PatentAvailabilityUnknownFiling Date2014-03-11Publication Date2019-05-08
Patent
Publication NumberUS 10272115StatusIssued PatentAvailabilityUnknownFiling Date2013-03-12Publication Date2019-04-30
The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
We found 128 documents that match your Search
Research Grants: 8
Patents: 114
Clinical Trials: 2
SEC Filings: 4

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in